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Sarcoidosis is an inflammatory, granulomatous disease of unknown etiology that most commonly afflicts the
lungs. Despite aggressive immunosuppressive therapies, many sarcoidosis patients still chronically present
significant symptoms. Infliximab, a therapeutic tumor necrosis factor alpha (TNF-) monoclonal antibody
(MAb), produced a small but significant improvement in forced vital capacity (FVC) in sarcoidosis patients in
a double-blind, placebo-controlled, phase II clinical trial. In the current study, serum samples from this
clinical trial were assessed to evaluate the underlying hypothesis that treatment with infliximab would reduce
systemic inflammation associated with sarcoidosis, correlating with the extent of clinical response. A 92-
analyte multiplex panel was used to assess the expression of serum proteins in 134 sarcoidosis patients
compared with sera from 50 healthy controls. A strong systemic inflammatory profile was associated with
sarcoidosis, with 29 analytes significantly elevated in sarcoidosis (false-discovery rate, <0.05 and >50% higher
than controls). The associated analytes included chemokines, neutrophil-associated proteins, acute-phase
proteins, and metabolism-associated proteins. This profile was evident despite patients receiving corticoste-
roids and immunosuppressive therapies. Following infliximab treatment, sarcoidosis patients expressing the
highest levels of TNF-, who had more severe disease, had the greatest improvement in FVC and reduction in
serum levels of the inflammatory proteins MIP-1 and TNF-RII. This study supports the need for further
exploration of anti-TNF therapy for chronic sarcoidosis patients, particularly for those expressing the highest
serum levels of TNF-.
Sarcoidosis is a chronic inflammatory disease characterized
by noncaseating granulomas consisting primarily of T cells and
macrophages, found most commonly in the lungs and lym-
phatic system (1, 15). Granulomas also form in other tissues,
such as the skin (subcutaneous), eyes, liver, joints, and heart, in
a subset of patients. The mechanisms initiating and promoting
granuloma formation are not well established, and virus-, bac-
terium-, or inorganic-molecule-dependent mechanisms have
been proposed (1). The inflammatory profile of sarcoidosis is
generally characterized by Th1-associated cytokines (including
interleukin 12 [IL-12], gamma interferon [IFN-], and IL-18)
and molecules associated with chronic granulomatous inflam-
mation (including angiotensin-converting enzyme and tumor
necrosis factor alpha [TNF-]). TNF- is critical in the devel-
opment of granulomas in various systems and is presumed to
be important in the etiology of sarcoidosis.
For patients with persistent chronic sarcoidosis who would
require continuous corticosteroid administration, alternative
immunosuppressive (cytotoxic) and antimalarial agents are
sometimes used. However, the unproven efficacy and consid-
erable long-term toxicity of these agents underscore the need
for safer alternatives with demonstrable efficacy (1).
In various case studies, the TNF--neutralizing monoclonal
antibody (MAb) infliximab (Centocor Ortho Biotech, Inc.,
Malvern, PA) has been reported to be efficacious in the treat-
ment of some patients with refractory sarcoidosis (3). To eval-
uate the safety and efficacy of infliximab in chronic pulmonary
sarcoidosis, a multicenter, randomized, double-blind, placebo-
controlled, phase II clinical study was undertaken (2). The
study examined chronic pulmonary sarcoidosis patients who
were symptomatic despite ongoing immunosuppressive ther-
apy with corticosteroids and/or other agents. In this study,
infliximab demonstrated a significant improvement in ventila-
tory restriction after 24 weeks of treatment (P  0.038 com-
pared with placebo). From post hoc analyses, improvement in
extrapulmonary severity after 24 weeks was observed in the
infliximab group, but not in the placebo group (12).
The underlying hypothesis for the current study is that treat-
ment with infliximab will reduce systemic inflammation asso-
ciated with sarcoidosis, correlating with the extent of clinical
response. Patients expressing the highest levels of inflamma-
tory burden before treatment are anticipated to respond best
to infliximab. The aims of the current study to evaluate this
hypothesis were to (i) evaluate the systemic inflammatory pro-
file associated with sarcoidosis and the presentation of disease
severity, (ii) establish the impact of TNF- neutralization on
* Corresponding author. Mailing address: Department of Biomark-
ers, Centocor Research & Development, Inc., 145 King of Prussia
Road, Radnor, PA 19087. Phone: (610) 651-6411. Fax: (610) 993-7864.
E-mail: mloza@its.jnj.com.
† Supplemental material for this article may be found at http://cvi
.asm.org/.
 Published ahead of print on 20 April 2011.
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systemic inflammation in sarcoidosis, and (iii) determine
whether changes in inflammatory mediators correlate with
clinical response to infliximab. To achieve these aims, we eval-
uated a broad panel of inflammation-associated proteins in
serum samples obtained at baseline and week 24 from the
sarcoidosis study population and compared them with serum
samples from a healthy control population. Baseline concen-
trations of the serum analytes were tested for associations with
disease status and correlations with clinical measurements of
disease severity and clinical response to infliximab treatment.
The impact of infliximab treatment on systemic inflammation
associated with sarcoidosis was investigated by comparison to
the placebo group for changes in serum levels from baseline to
the week 24 endpoint.
MATERIALS AND METHODS
Inclusion and exclusion criteria, demographic and clinical characterization of
the sarcoidosis patients, and clinical efficacy and safety results of the study (2),
including percent predicted forced vital capacity (ppFVC), St. George’s Respi-
ratory Questionnaire (SGRQ) total score, 6-minute walk distance (6MWD),
diffusing limit of carbon monoxide (DLCO), and extrapulmonary physician or-
gan severity tool (ePOST) score (12), have been previously reported. Placebo or
infliximab at 3 or 5 mg/kg of body weight was administered at weeks 0 (baseline),
2, 6, 12, 18, and 24. Peripheral venous blood samples were collected before study
agent administration at baseline and week 24 (the primary endpoint time point).
Serum samples from 50 healthy control subjects were purchased from a com-
mercial vendor (Bioreclamation, Hicksville, NY). Qualification for healthy status
was evaluated from a self-reported questionnaire. Exclusion criteria for healthy
controls included not feeling healthy at the time of donation; headache or fever
in the past week; risky sexual activity in the past year; having ever tested positive
for or been treated for sexually transmitted disease; a history of alcoholism or
drug abuse; having or having had one or more of the diseases in a broad panel;
having been under the care of a physician, having had surgery, or having taken
any prescription medications in the past year; and, for females, being currently
pregnant or having been pregnant in the past 6 weeks or being postmenopausal.
Basic demographic information (age and gender) was available for the healthy
control subjects.
The institutional review board for each institution approved the study. All
subjects provided written informed consent.
Measurement of serum analyte concentrations. Serum samples were analyzed
for the concentrations of 92 inflammation-associated proteins by Rules Based
Medicine, Inc., using their human MAP v1.6 panel (18) of Luminex-based mul-
tiplex assays, with measurements for IL-17, IL-18, and IL-23 added to the panel.
The least detectable dose (LDD) was defined as the back-calculated concentra-
tion for the mean plus 3 standard deviations (SD) of the luminescence values of
20 blank readings (the LDD for each analyte is shown in Table S1 in the
supplemental material). Concentrations below the lowest resolved standard
and/or the LDD were transformed to a value of 0.5 LDD. Baseline serum
samples from sarcoidosis patients and healthy controls were analyzed at the same
time by Rules Based Medicine, and all serum samples underwent the same
number of freeze-thaw cycles. The week 24 serum samples from sarcoidosis
patients were analyzed independently of the baseline samples, with 10 baseline
samples analyzed with week 24 samples to assess potential batch effects by
Bland-Altman plot and correlation analyses.
Statistical analyses. Nonparametric tests were generally used for analyses
because the majority of analytes (original scale and log transformed) were not
n-normally distributed (according to the D’Agostino and Pearson omnibus test
for normality) for both sarcoidosis and healthy control populations. Mann-
Whitney U tests and Kruskal-Wallis tests were used to compare continuous
variables among 2 and 3 groups, respectively. Rank-based tests using Spearman’s
correlations were used to test for correlations among continuous variables. Gen-
eral linear model analyses, adjusted for multiple independent variables, were
performed. For comparisons of treatment responses, the response for each
individual patient was expressed as log2(week 24 value/baseline value), and these
calculated relative values were tested for differences between infliximab and
placebo treatment groups. To evaluate the validity of the analyses, model as-
sumptions, such as normality and homogeneity of variance, were examined. The
significance level was reported as a P value or a false-discovery rate (FDR) (20)
to control for multiple-testing inflation of the false-positive rate based on the
Benjamin-Hochberg procedure, calculated using the R program QVALUE v.1.0
(7). An FDR of 0.05 was considered significant, and a P value of 0.05 (with
an FDR of 0.05) was considered a nominally significant trend. Unsupervised
clustering was performed using hierarchical-standard clustering with complete
linkage and a Euclidean similarity metric (OmniViz v6.0 software; BioWisdom,
Inc.).
RESULTS
Associations of baseline serum analyte levels and sarcoid-
osis. Serum samples were collected from 134 patients with
chronic pulmonary sarcoidosis at baseline, before the first in-
fusion of placebo (n  44), infliximab at 3 mg/kg (n  45), or
infliximab at 5 mg/kg (n  45). Serum samples were also
obtained during the primary endpoint visit at week 24 (pla-
cebo, n  42; infliximab at 3 mg/kg, n  43; infliximab at 5
mg/kg, n  45). Basic demographic and baseline clinical char-
acterization of the sarcoidosis patients and their background
therapy are provided in Table 1. In addition, serum samples
were obtained from 50 healthy control subjects independently
of the clinical trial. The serum concentrations of 92 inflamma-
tion-associated analytes were measured. For the baseline se-
rum samples, the concentrations of 26 analytes were below the
LDD of the assay for 75% of both sarcoidosis patients and
healthy control subjects, and 2 additional analytes were below
the LDD for 75% of sarcoidosis patients and 50% of
healthy controls (see Table S1 in the supplemental material).
These analytes were excluded from further statistical analyses
of the baseline samples.
To establish the baseline systemic inflammatory profile as-
sociated with sarcoidosis, the serum analyte levels in the sar-
coidosis and control populations were compared. In total, 35
analytes were associated with sarcoidosis, 29 were not associ-
ated with sarcoidosis, and 28 were below the LDD of the assay
platform. Of the 35 analytes associated with sarcoidosis, the
median serum levels of 29 analytes were 50% higher in sar-
coidosis cases than in controls and those of 6 analytes were
50% lower in sarcoidosis cases than in controls, with an FDR
of 0.05 (Table 2). The significantly associated analytes with
the greatest differences between sarcoidosis cases and controls
included CD40L, brain-derived neurotrophic factor (BDNF),
epidermal growth factor (EGF), CC-chemokine ligand
5/RANTES (regulated upon activation, normally T-cell ex-
pressed, and presumably secreted), myeloperoxidase, and
ENA-78 (epithelial-derived neutrophil-activating protein 78),
each greater than 7-fold higher in the sarcoidosis than in the
control population (Fig. 1A to F); IGF-1 (insulin-like growth
factor 1) and IgE were both decreased in sarcoidosis patients
more than 8-fold relative to controls (Fig. 1G and H). TNF-
levels were significantly increased in sarcoidosis patients, but
with nearly a majority (47%) of sarcoidosis patients having
levels below the LDD (Fig. 1I). MIP-1, an infliximab-sensitive
chemokine (detailed in Changes in serum analyte concentra-
tions after infliximab treatment below), was also significantly
associated with sarcoidosis (3.5-fold; FDR  108).
The ratio of males to females was higher in the sarcoidosis
patient population than in the healthy control population
(57:77 versus 25:25, respectively), which had the potential to
introduce gender bias in the results. Indeed, substantial differ-
ences were observed between males and females in the sar-
coidosis population. Females had more severe disease than
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males, with a significantly higher SGRQ total score (P  3.5 
105) and lower 6MWD and DLCO (P  109 for both)
(Table 1). Fifteen of 64 (23%) analytes were significantly dif-
ferent (FDR  0.05; 50% difference) between males and
females in the sarcoidosis population. Because of the differ-
ences between males and females within sarcoidosis cases,
statistical analyses for comparisons of cases and controls in-
cluded stratification by gender. Thirty-one of the 35 analytes
significantly associated with sarcoidosis remained significant
when adjusted for gender, with TNF- dropping out for fe-
males and IL-7, IL-1 receptor antagonist (IL-1RA), and CD40
dropping out for males. Of the 29 analytes not associated with
sarcoidosis, 19 analytes had an FDR of 0.05 and/or an abso-
lute value of signed fold of 1.5 for sarcoidosis cases versus
controls for each of the gender-unrestricted or -restricted anal-
yses, with the other 10 analytes showing an association only in
gender-restricted analyses (see Table S2 in the supplemental
material).
Correlation of baseline serum analyte levels with clinical
measurements. None of the analytes obtained at baseline were
significantly associated with baseline clinical measurements
(ppFVC, SGRQ total score, 6MWD, DLCO, or ePOST score)
after FDR adjustment in both male and female sarcoidosis
populations. Among analytes significantly associated with sar-
coidosis, ENRAGE (extracellular newly identified receptor for
advanced glycation end product)/S100A12 was correlated with
the ppFVC with nominal significance for both males and fe-
males (r  0.32; P  0.014), and leptin was significantly
correlated with SGRQ total scores in males only (r  0.44;
FDR  0.0039) (see Fig. S1 in the supplemental material). A
list of r, P, and FDR values for analytes that achieved signifi-
cant correlations (FDR  0.05) in either gender or nominal
significant correlations in the total population is provided in
Table S3 in the supplemental material.
Extrapulmonary organ involvement was significantly corre-
lated (FDR  0.05) with 7 analytes in the total sarcoidosis
study population, including the acute-phase proteins C-reac-
tive protein (CRP) and ferritin (see Table S4 in the supple-
mental material). For the severity of extrapulmonary organ
involvement (i.e., the ePOST score), no significant correlations
were seen in gender-stratified analyses (data not shown).
The correlation between baseline concentrations of the se-
rum analytes and treatment-associated changes in clinical pa-
rameters from baseline to week 24 was evaluated. There were
no significant correlations (FDR  0.05) between baseline
analyte concentrations and changes from baseline to week 24
in ppFVC, SGRQ, 6MWD, or ePOST in infliximab treatment
groups.
Changes in serum analyte concentrations after infliximab
treatment. Having established the baseline systemic inflam-
matory profile associated with sarcoidosis, whether treat-
ment with infliximab could significantly down-modulate this
inflammatory profile was examined. After exclusion of 30
analytes for being below the detection level and 12 analytes
for uncorrectable batch effects, the change in the serum
concentrations of 50 analytes from baseline to week 24 was
examined for the 3 treatment groups in the sarcoidosis pa-
tient population. The results for analytes with FDRs of
0.05 or P values of 0.05 for differences between the
infliximab and placebo groups are shown in Table S5 in the
TABLE 1. Demographics and baseline clinical phenotypes in sarcoidosis patients
Characteristic
Total Female Male P value
(female vs. male)Mean SD Mean SD Mean SD
Patients (n) 134 77 57
Gender (% male) 57.5 0.0 100.0
Age (yr) 46.9 9.3 49.1 9.0 45.3 9.1 0.016
ppFVC 68.5 9.8 69.2 11.0 68.0 8.9 0.45
SGRQ total score 46.8 18.9 54.4 17.2 41.2 18.2 3.5  105
6MWD 455 113 383 99 508 92 109
DLCO 17.6 6.6 12.7 4.1 21.2 5.8 109
ePOST score 2b 0–6b 4 0–8 1 0–4 0.018
BMIa 30.5 6.6 32.8 7.0 28.7 5.8 4.5  104
Race 0.0023
Asian (%) 1.5 1.8 1.3
Black (%) 30.6 45.6 19.5
Caucasian (%) 66.4 49.1 79.2
Other (%) 1.5 3.5 0.0
Baseline therapy 0.14
Immunoc (%) 10.4 15.8 6.5
OCS (%) 51.5 43.9 57.1
OCS 	 Immuno (%) 38.1 40.4 36.4
Organ involvement
Extrapulmonary (%) 66.7 72.7 62.3 0.26
Skin (%) 12.7 17.5 9.1 0.15
Eyes (%) 4.5 5.3 3.9 0.71
a BMI, body mass index.
b Median and interquartile range are presented for ePOST scores.
c Immuno, immunomodulators, including azathioprine, chloroquine, hydroxychloroquine, and methotrexate.
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supplemental material and are shown for select analytes in
Fig. 2. The ratio of posttreatment concentrations to baseline
concentrations for each analyte was calculated for each in-
dividual patient. The significance of the differences in the
median concentrations between the 3-mg/kg and 5-mg/kg
infliximab treatment groups and the placebo group was
tested. TNF- concentrations increased during treatment
with infliximab, consistent with observations for other inf-
liximab studies using this multiplex assay (unpublished
data). Despite an FDR of 0.05 for the 5-mg/kg infliximab
treatment compared with placebo, the difference in the me-
dian concentrations of MIP-1, CD40, TNF-RII, and
ICAM-1 were less than 40% from the placebo and not
significant for the 3-mg/kg infliximab group versus placebo.
Denser time courses of analyte levels in serum were not
available for analysis using the Rules Based Medicine panel.
However, clinical laboratory measurements for CRP and
ICAM-1 were performed more frequently (see Fig. S2 in the
supplemental material). There was a modest decrease in
CRP levels at 2 weeks postdosing with 10 mg/kg infliximab
relative to baseline (median, 25% decrease; P  0.003 ver-
sus placebo), but it rebounded to baseline levels by week 6
(median, 0% change from baseline). ICAM-1 levels also
were significantly decreased at week 2, but in both the 3- and
10-mg/kg infliximab groups (33% decrease; P  106 versus
placebo). Unlike CRP, the decrease in ICAM-1 levels was
maintained throughout the study period, consistent with the
results from the Rules Based Medicine panel.
Changes from baseline in concentrations of MIP-1 and
TNF-RII were inversely correlated (with nominal signifi-
cance) with changes from baseline in both ppFVC (r 
0.39 and 0.30) and 6MWD (r  0.38 and 0.48) for
the 5-mg/kg infliximab treatment group (Fig. 3). Impor-
tantly, changes in these analytes had (nonsignificant) direct
correlations with changes in ppFVC and 6MWD in the pla-
cebo group (Fig. 3). Multivariate modeling with adjustments
TABLE 2. Analytes significantly associated with sarcoidosis
Analytea
Females Males Males 	 females

 Foldb FDR 
 Fold FDR 
 Fold FDR
Sarcoidosis  control
CD40 ligand 169 108 109 108 128 108
Brain-derived neurotrophic factor 47.5 108 48.0 108 48.7 108
RANTES 27.0 108 22.8 108 24.7 108
Myeloperoxidase 30.3 108 7.1 1.0  108 19.1 108
EGF 30.5 1.7  104 11.4 8.6  105 18.5 9.0  108
ENA-78 13.16 108 7.88 108 7.59 108
SGOT 5.59 2.7  106 7.90 108 6.69 108
Ferritin 2.87 5.8  105 7.76 108 4.87 108
Growth hormone 5.88 1.9  104 3.94 3.8  103 4.81 6.4  106
Eotaxin 3.80 2.0  108 5.32 108 4.78 108
Insulin 2.11 0.026 6.06 8.9  104 3.56 8.4  105
MIP-1 4.08 4.0  108 3.26 108 3.51 108
MMP-3 3.04 6.6  105 3.25 5.0  108 3.24 108
ENRAGE 4.08 4.2  107 1.61 0.012 2.78 2.0  108
IL-18 3.07 108 2.76 108 2.74 108
PAI-1 2.47 108 2.62 108 2.69 108
Leptin 2.55 4.6  106 4.85 4.5  105 2.68 8.2  106
TIMP-1 2.76 108 2.56 108 2.60 108
IL-7 3.68 4.2  107 1.00 1.2  104 2.40 108
CRP 2.55 6.5  103 2.08 4.6  106 2.25 2.8  103
IL-1RA 2.65 9.5  105 1.46 0.022 2.18 1.3  103
TNF- 1.23 0.061 2.08 0.030 2.16 5.3  103
Glutathione S-transferase 2.40 1.2  106 1.83 2.0  104 2.04 108
Stem cell factor 3.01 2.0  108 1.70 4.5  105 2.00 108
Prostatic acid phosphatase 2.26 1.0  108 1.70 1.2  104 1.94 108
IL-16 2.13 5.0  108 1.80 8.0  108 1.84 108
VEGF 1.82 1.4  104 1.71 1.2  104 1.68 1.6  107
MCP-1 1.47 7.4  105 1.70 1.9  106 1.63 108
CD40 1.92 4.2  105 1.25 6.3  103 1.62 8.0  107
Sarcoidosis  control
IGF-1 10.41 108 34.60 108 20.4 108
IgE 7.97 1.2  106 10.99 6.4  106 9.35 108
-2 Macroglobulin 2.89 5.1  107 8.17 108 5.85 108
MIP-1 1.90 2.7  104 3.90 108 2.99 108
Tissue factor 2.30 4.2  107 2.10 5.0  108 2.15 108
Apolipoprotein CIII 1.49 0.024 2.90 7.8  106 2.10 9.7  107
a Analytes significantly associated with sarcoidosis (FDR  0.05 and signed-fold  1.5) in the total populations (males plus females) are reported. Analytes that
were significantly associated with sarcoidosis in only females or only males are shown in boldface. SGOT, serum glutamic oxaloacetic transaminase; VEGF, vascular
endothelial growth factor.
b 
 Fold represents the signed fold for the median in sarcoidosis divided by the median in healthy control populations. When the median expression in the sarcoidosis
population was lower than that in controls, the opposite of the reciprocal is reported.
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for gender and the respective baseline clinical measurement
did not significantly impact the observed correlations.
Changes in TNF-RII and MIP-1 were strongly correlated
(r  0.70) and thus were not additive in their correlation
with changes in ppFVC and 6MWD.
Stratification based on TNF- levels. Infliximab targets
TNF-, and therefore, baseline serum concentrations of the
molecule may be critical to consider when interpreting the
impact of infliximab on clinical and biomarker endpoints. Be-
cause of the high proportion of samples with TNF- levels
below the LDD of 4 pg/ml, correlation analyses for TNF-may
be unreliable. As an alternative approach, sarcoidosis patients
were classified as having TNF- levels within (LDD [TNF-
-high], 53%) or below (LDD [TNF--low], 47%) the limits
of quantification. The baseline ppFVC (P  0.0016) (Fig. 4A)
and 6MWD (P 0.020) (Fig. 4B) were both significantly lower
in the “TNF--high” than in the “TNF--low” subset. Signifi-
cance was retained (P  0.0025 and 0.024, respectively) after
multivariate adjustment for age, gender, and baseline therapy
(oral corticosteroid [OCS], immunomodulator, or OCS plus
immunomodulator). The frequency of extrapulmonary presen-
tations in the sarcoidosis population was significantly higher in
the TNF--high (78%) than in the TNF--low subset (53%)
(P  0.0051; Fisher’s exact test). The cumulative severity of
extrapulmonary involvement was also higher in the TNF--
high subset than in the TNF--low subset (median [interquar-
tile range]  4 [1 to 8] and 1 [0 to 3.5], respectively; P 
0.00050) (Fig. 4C).
ppFVC significantly improved after infliximab treatment
compared with placebo in the TNF--high subset (P  0.022),
but not in the TNF--low subset (P  0.34). Importantly, this
difference was maintained after adjustment for gender, age,
baseline ppFVC, and baseline therapy (OCS versus OCS plus
immunomodulator) in the multivariate general linear model
analysis (P  0.0025 versus 0.54 for the TNF--high and -low
subsets, respectively). The adjusted least-squares means from
the multivariate model were increases of 4.3 and 1.6 in ppFVC
after infliximab treatment for the TNF--high and -low sub-
sets, respectively (compared with a 0.9 decrease and a 0.4
increase, respectively, with placebo) (Fig. 4D). Changes in the
FIG. 1. Association between baseline analyte concentrations and sarcoidosis. The baseline concentrations for the indicated analytes (y axes) are
shown for male and female subpopulations in the healthy control and sarcoidosis cohorts. Each symbol represents an individual patient. Median
and interquartile range are shown for each population. The dashed lines indicate the LDDs for the analyte. (A to F) Top 6 of 29 analytes with
increased concentrations associated with sarcoidosis. (G and H) Top 2 of 6 analytes with decreased concentrations associated with sarcoidosis.
(I) TNF- concentrations were increased in sarcoidosis but below the LDD in nearly half of patients.
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SGRQ total score, 6MWD, and ePOST score were not signif-
icantly different for infliximab treatment compared with pla-
cebo in either subset.
Expression levels of 11 of the 34 proteins significantly over-
or underexpressed in sarcoidosis patients (excluding TNF-)
were significantly higher in the TNF--high than in the TNF-
-low subset (Table 3). This includes increased expression of
MIP-1, which was decreased in the overall sarcoidosis study
population versus healthy controls. In addition, 4 analytes
not significantly elevated in the sarcoidosis population over-
all (ICAM-1, IL-8, monocyte-derived chemokine, and thy-
roid-stimulating hormone) were increased in the TNF--
high subset.
When the sarcoidosis population was stratified into subsets
based on TNF- expression, the effect of infliximab on MIP-1
was more pronounced than in the total population. The de-
crease in MIP-1 serum levels was greater in the TNF--high
subset than the TNF--low subset after 5-mg/kg infliximab
treatment (1.82- versus 1.35-fold relative to placebo, respec-
tively; P 0.0015) (Fig. 4E). Levels of TNF-RII also decreased
FIG. 2. Change in serum analyte concentrations after 24-week infliximab treatment. Results are shown for analytes demonstrating FDRs of
0.05 (†) for differences between the infliximab treatment group (3 or 5 mg/kg) and the placebo group or P 0.05 (*) for both the 3- and 5-mg/kg
treatment groups versus placebo. The ratio of the analyte concentration after 24-week treatment to the baseline concentration per patient is
expressed as the signed fold (y axis) for each treatment condition. Box (median and interquartile range) and whiskers (range) plots are presented.
FIG. 3. Correlation between changes in analyte concentrations and clinical measures after infliximab treatment. Changes in the concentrations
of MIP-1 as correlated with ppFVC (A) and 6MWD (B) and changes in the concentrations of TNF-RII as correlated with ppFVC (C) and 6MWD
(D), expressed as log2 of the week 24/baseline level (x axis), for 24-week treatment of sarcoidosis patients with placebo, 3 mg/kg infliximab, or 5
mg/kg infliximab are plotted for each patient analyzed.
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in the TNF--high subset (21% and 29%, respectively, for the
3-mg/kg and 5-mg/kg infliximab groups) compared with pla-
cebo.
Overall, the results demonstrate that patients expressing
higher levels of TNF- presented with more severe pulmonary
and extrapulmonary disease and demonstrated greater im-
provement in ppFVC and a greater decrease in MIP-1 after
treatment with infliximab.
DISCUSSION
Using a 92-analyte panel of inflammation-associated mark-
ers, we have demonstrated a strong systemic inflammatory
profile associated with chronic sarcoidosis. Among the associ-
ated inflammatory mediators, serum levels of MIP-1 and
TNF-RII were significantly reduced after treatment with inf-
liximab and were associated with greater improvements in
FVC and 6MWD. Sarcoidosis patients expressing the highest
levels of TNF-, who had more severe pulmonary and ex-
trapulmonary disease, had the greatest improvement in per-
cent predicted FVC and reduction in MIP-1 and TNF-RII
levels after infliximab treatment.
Twenty-nine of 64 analytes quantifiable in the sera of sar-
coidosis patients and/or healthy controls were significantly el-
evated in sarcoidosis patients by at least 1.5-fold over controls.
Importantly, these associations were independently observed
in both the male and female populations in the gender-strati-
fied analyses. Associated markers include chemokines, neutro-
phil-associated proteins, acute-phase proteins, coagulation fac-
tors, and regulators of metabolism. Many of these associations
have not been previously reported for sarcoidosis or have been
reported only for associations with expression in airways, but
not systemic expression. This strong systemic inflammatory
FIG. 4. Stratification by TNF- expression. Sarcoidosis patients were stratified into subsets based on having TNF- levels below () or above
() the LDD. (A to C) The baseline ppFVC (A) and 6MWD (B) in the total study population and the baseline ePOST score (C) in sarcoidosis
patients presenting with extrapulmonary involvement are shown for each patient. Medians (bars) and P values for differences between the
TNF--defined subsets are reported. (D) Adjusted least squares means (plus 95% confidence intervals) for the change in ppFVC from baseline
to week 24 after infliximab (3- and 5-mg/kg) treatment or placebo. The means were adjusted for gender, age, baseline ppFVC, and baseline therapy
(OCS versus OCS plus immunomodulator), and P values for infliximab versus placebo treatment were calculated in General Linear Model
analyses. (E) Changes in MIP-1 serum levels after 24-week treatment with placebo or infliximab at the indicated dose are expressed as signed
fold over baseline for the TNF--defined subsets for each patient. Medians (bars) and P values for infliximab versus placebo treatment are shown.
TABLE 3. Baseline analyte levels in TNF--defined subsets
Analytea Foldb FDRc
MIP-1 4.62 2.6  107
IL-1RA 2.91 5.1  106
EGF 2.90 0.00039
TNF- 2.82 3.2  108
CRP 2.52 0.031
Myeloperoxidase 2.43 5.4 107
ENRAGE 2.11 0.0016
Growth hormone 2.00 0.044
CD40 Ligand 1.84 0.00035
IL-8 1.70 5.0  105
ICAM-1 1.62 3.9  106
CD40 1.61 3.2  108
MDC 1.60 3.4  105
Thyroid-stimulating hormone 1.53 0.0012
TNF-RII 1.51 1.8  106
IL-18 1.51 6.2  105
a Listed are analytes that are significantly different between the TNF- 
LDD subset and the TNF-  LDD subset (FDR  0.05 and fold  1.5).
b Fold expression of the analyte in the TNF-  LDD subset over that in the
TNF-  LDD subset.
c FDR for the difference in expression of the analyte in the TNF-  LDD
subset and in the TNF-  LDD subset.
VOL. 18, 2011 INFLAMMATORY PROFILE IN PULMONARY SARCOIDOSIS 937
 o
n
 M
arch 8, 2012 by UNIVERSITEIT M
AASTRICHT
http://cvi.asm
.org/
D
ow
nloaded from
 
profile prior to infliximab therapy was evident despite the use
of corticosteroids and immunosuppressive therapy, and many
of these proteins remained elevated after anti-TNF therapy.
This suggests that current therapies are still unable to com-
pletely suppress the inflammatory response in these patients
with sarcoidosis. Why inflammation was substantially reduced
in only a small fraction of the infliximab-treated population
remains unclear. Potential explanations include the fact that
longer active treatment periods are required; there is a limited
subset of patients in which TNF- is a central driver of sys-
temic inflammation, for example, patients with severe extrapul-
monary pathology as discussed above; and TNF- contributes
to only a limited component of the overall ongoing inflamma-
tion associated with sarcoidosis.
The serum disease profile illustrates an important role for
chemokines in the ongoing inflammation associated with sar-
coidosis. All chemokines in the panel were significantly asso-
ciated with sarcoidosis (MCP-1, RANTES, ENA-78, IL-16,
etc.). Our findings of these elevated chemokines in sarcoidosis
support the following published findings. MCP-1 has been the
chemokine most commonly reported to be overexpressed in
sarcoidosis, with reports of increased expression in the air-
ways (6, 10, 11, 16, 21) and systemically in serum (9, 11, 21).
RANTES (10, 14, 17) and ENA-78 (22) were reported to have
increased expression in the airways in sarcoidosis; we report
here an elevation in serum. IL-8, a neutrophil chemoattractant,
was reported to be elevated in the airways (6) and in plasma (4)
and was found to be inversely correlated with FVC (23) in
sarcoidosis patients. We report here that serum levels of IL-8
were modestly inversely correlated with FVC. Our finding of
elevated eotaxin in the sera of patients with sarcoidosis is
novel.
MIP-1 was reported to be elevated in the bronchoalveolar
lavage (BAL) fluid of sarcoidosis patients at all stages of the
disease, whereas MIP-1 was elevated only in chronic or pro-
gressive disease (5). Increased serum concentrations of
MIP-1 have also been reported by Hashimoto et al. to be
associated with sarcoidosis (9). Although serum levels of
MIP-1 were decreased in the sarcoidosis population in the
current study, MIP-1 was overexpressed in the TNF--high
subset of sarcoidosis patients. This subset also was associated
with lower percent predicted FVC, consistent with the previous
observations of MIP-1 being upregulated only in progressive
disease. Treatment with infliximab resulted in a significant
decrease in MIP-1, as well as a trend toward decreases in IL-8
and eotaxin, thus supporting a role for TNF- in regulating
chemokine levels in sarcoidosis.
Interestingly, the elevation of myeloperoxidase and
ENRAGE and the inverse correlation of IL-8 with FVC sug-
gests a role for neutrophil activation and phagocytic function in
sarcoidosis. It has been previously demonstrated that increased
neutrophils in the BAL fluid are associated with a worse prog-
nosis (8) and that increased neutrophils in BAL fluid correlate
with the BAL fluid levels of IL-8 (8). Based on these results,
the utility of monitoring neutrophil-associated proteins in the
serum during the course of disease and treatment warrants
further investigation.
Sarcoidosis is a disease in which a Th1 phenotype is known
to predominate (24), and IL-12, IL-18, and IFN- have been
reported to be elevated in sarcoidosis (19). While IL-18 was
elevated in the sarcoidosis patients in our study, IL-12 and
IFN- were not, as these analytes were below the limit of
detection of the assay platform. This platform is designed for
large multianalyte profiling, and thus, the detection of the
individual analytes is typically not as sensitive as a standard
single-analyte assay would be. In addition, these proteins are
labile and may be affected by long-term storage and freeze-
thaw cycles.
The importance of TNF- in the development of granulo-
matous inflammation has been demonstrated in various model
systems (24). However, it is unclear how this translates to
sarcoidosis pathology. TNF- was found at low levels in sar-
coidosis patients, but below the quantification limit in almost
half of that population. When the sarcoidosis population was
stratified into subsets based on relative levels of TNF- (above
versus below the LDD), the subset with higher TNF- expres-
sion presented with more severe pulmonary and extrapulmo-
nary disease and demonstrated a greater increase in percent
predicted FVC than the subset with low TNF-. Patients in the
higher TNF--expressing group also had a more pronounced
inflammatory profile and larger decreases in MIP-1 and TNF-
RII serum levels following infliximab treatment. MIP-1 gene
expression has previously been demonstrated to decrease in
peripheral blood mononuclear cells after treatment with a
TNF inhibitor, etanercept, in patients with rheumatoid arthri-
tis (13). Decreases in TNF-RII following anti-TNF treatment
have not previously been reported. These markers may repre-
sent a positive pharmacodynamic and response signature to
anti-TNF treatment. Overall the results for the TNF--strati-
fied subsets support the hypothesis that elevated systemic lev-
els of TNF- are associated with more severe disease and
therefore represent a population potentially more responsive
to anti-TNF- therapy. Therefore, stratification of disease
populations based on TNF- levels may be warranted in future
studies of anti-TNF- therapeutics to assess whether greater
clinical efficacy can indeed be attained.
Increased TNF- levels were observed following infliximab
treatment, an apparently paradoxical observation that was nev-
ertheless anticipated. Infliximab stably binds circulating
TNF-, thus stabilizing generally short-lived circulating TNF.
It is hypothesized that as new TNF- is released into circula-
tion, it is likewise bound by infliximab. This would result in an
increased pool of nonactive, antibody-bound TNF-. From
previously reported pharmacokinetic analyses (2), there were
substantial levels of free infliximab in circulation at the week 24
endpoint, suggesting that most TNF- detected was drug
bound. Although free versus bound TNF- has not been for-
mally tested, this is a common observation for anti-TNF ther-
apies in diseases for which they are potently efficacious. In-
deed, this was expected and served as a positive control.
In summary, we have demonstrated a 35-analyte disease
profile of sarcoidosis that is reflective of a significant degree of
systemic inflammation, with many of the inflammation-associ-
ated analytes being novel findings. The results reinforce a
major role for chemokines in sarcoidosis and provide evidence
for granulocyte-mediated inflammation. Overall, infliximab
treatment did not result in a substantial reduction of the pro-
teins in the 35-analyte panel; however, MIP-1 and TNF-RII
did show decreases following treatment with infliximab.
The current study supports the need for further exploration
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of anti-TNF therapy for sarcoidosis patients who remain symp-
tomatic despite the use of glucocorticosteroids and/or cytotoxic
agents, particularly those expressing the highest serum levels of
TNF-. The impacts of novel therapies with different mecha-
nisms of action on the disease profile will be important in
understanding the heterogeneity of the disease. Identification
of biomarkers of treatment response may lead to improved
management of the unpredictable clinical course of sar-
coidosis.
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